CurrentCommunity-CarePolicy N/A

Nipocalimab for generalized myasthenia gravis — Medical Benefit Medication Utilization Policy

Medical benefit medication utilization policy governing initial and continuation coverage criteria, quantity limits, authorization period, and billing codes for nipocalimab in members with generalized myasthenia gravis.

Policy Summary

PayerCommunity-Care

PolicyNipocalimab for generalized myasthenia gravis — Medical Benefit Medication Utilization Policy

Policy CodePolicy N/A

Change TypeNo material changes

Effective Date

Next Review DateSep 1, 2025

Key ActionObtain prior authorization and document neurologist prescription, diagnosis, positive serologic test, age, MGFA class, MG-ADL score, prior medication trials, and attestation that therapy will not be combined with other biologic MG therapies.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

≥12minimum patient age

≥6MG-ADL requirement

II–IVeligible MGFA class

1 yrauthorization period

J9256billing code

Coverage Criteria for Nipocalimab

Continuation Therapy

Covered for continuation when ALL of the following are met

Continuation Criteria: 1) Ongoing diagnosis of generalized myasthenia gravis; 2) Attestation of a positive clinical response to therapy; 3) Will not be used in combination with other biologic therapies for myasthenia gravis.

Authorization period if approved: up to 1 year (subject to benefit changes).

Use of nipocalimab in combination with other biologic therapies for myasthenia gravis is not allowed and requests must include an attestation that the drug will not be administered concurrently with other biologic MG treatments.

Coding and Key Clinical Thresholds

Applicable HCPCS CodesHCPCSCovered

J9256

Injection, nipocalimab-aahu, 3 mg

MG-ADL total score

MG-ADL total scoreMyasthenia Gravis-Activities of Daily Living (MG-ADL) total score ≥ 6

Policy Summary

PayerCommunity-Care

PolicyNipocalimab for generalized myasthenia gravis — Medical Benefit Medication Utilization Policy

Policy CodePolicy N/A

Change TypeNo material changes

Effective Date

Next Review DateSep 1, 2025

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Provider Actions and Documentation Requirements

Prior Authorization

Prior Authorization and Authorization Period

Prior authorization is required. If approved, initial and continuation authorizations may be granted for up to 1 year (subject to benefit changes). Requests should indicate the requested authorization period and include clinical justification supporting the need for therapy and planned duration.

Prior authorization required prior to initiation of therapy
Authorization period: up to 1 year if approved (subject to benefit changes)

Step Therapy

Required Prior Medication Trials

Before approval, the following medication trials are required unless ineffective, not tolerated, or contraindicated: an acetylcholinesterase (AChE) inhibitor and one of the following: an oral corticosteroid or an oral non‑steroidal immunosuppressant. Document treatment attempts and reasons for discontinuation if applicable.

Trial of an acetylcholinesterase inhibitor (or documentation why it is ineffective/contraindicated/not tolerated)
Trial of either an oral corticosteroid OR an oral non‑steroidal immunosuppressant (or documentation why ineffective/contraindicated/not tolerated)

Documentation Required

Required Documentation

Include the following documentation with the prior authorization request: neurologist prescription or consultation, confirmed diagnosis of generalized myasthenia gravis, positive serologic test result (anti‑acetylcholine receptor or anti‑MuSK antibodies), patient age (≥ 12 years), MGFA class, baseline MG‑ADL total score, weight (for dosing), and documentation of prior medication trials and response or intolerance.

Prescription or consultation note from a neurologist
Diagnosis of generalized myasthenia gravis
Positive serologic test: anti‑acetylcholine receptor OR anti‑MuSK antibodies (lab report)
Patient age (≥ 12 years)
MGFA class (II–IV)
Baseline MG‑ADL total score (≥ 6)
Documentation of prior AChE inhibitor trial and trial of oral corticosteroid or oral non‑steroidal immunosuppressant
Patient weight (required for approval)

Denial Risk

Potential Denial Triggers

Common reasons for denial include missing or negative serologic testing, failure to meet age, MGFA class, or MG‑ADL score requirements, lack of required prior medication trials or inadequate documentation of trials/intolerance, requests to use in combination with other biologic therapies, and absence of neurologist involvement. Ensure all required fields and supporting records are provided to avoid delays or denial.

Missing or no positive serologic test for anti‑acetylcholine receptor or anti‑MuSK antibodies
Patient age < 12 years
MGFA class outside II–IV
MG‑ADL total score < 6
No documentation of prior AChE inhibitor trial
No documentation of trial of oral corticosteroid or oral non‑steroidal immunosuppressant (or lack of rationale for exemption)
Request to use in combination with other biologic therapies for myasthenia gravis
No neurologist prescription or consultation documented
Missing patient weight for dosing

Background

Generalized myasthenia gravis is an autoimmune neuromuscular disorder characterized by fatigable muscle weakness. Diagnosis typically relies on clinical assessment supported by serologic testing for anti‑acetylcholine receptor or anti‑MuSK antibodies, and severity is commonly classified using the Myasthenia Gravis Foundation of America (MGFA) system and the patient‑reported MG‑ADL score. This policy applies to members aged ≥ 12 years with MGFA Class II–IV and an MG‑ADL total score of ≥ 6, and it governs initial and continuation coverage, required trials of symptomatic and immunosuppressive therapies, documentation, prior authorization, and billing for nipocalimab.

OpenPayer

Nipocalimab for generalized myasthenia gravis — Medical Benefit Medication Utilization Policy

Coverage Criteria for Nipocalimab

Coding and Key Clinical Thresholds

Provider Actions and Documentation Requirements

Background

Definitions